Boston Scientific Likely to Miss Guidance Due to Cyberattack Impact
Boston Scientific disclosed that a recent cyberattack is likely affecting its third-quarter and full-year financial results, making it unlikely the company will meet previously provided guidance for net sales growth and adjusted earnings per share. The medical device maker stated in an SEC filing that while some revenue recovery is expected as operations resume globally, the complete impact remains uncertain. Boston Scientific plans to provide updated outlooks during its October 28 earnings call but emphasized the attack should not have a material long-term financial effect. The cyberattack disrupted manufacturing and order fulfillment for several weeks, though most global facilities are now operational again with distribution centers processing at or above normal levels. The incident is part of an ongoing trend in the medical device industry, where companies like Stryker, Medtronic, Intuitive Surgical, and Abbott have also faced similar disruptions. Analysts noted that Boston Scientific's situation differs from past attacks on peers due to its product mix and limited time left this year for revenue recovery. The company has already revised guidance twice in 2026 amid ongoing business challenges.